Silicon Valley Capital Partners increased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 3.7% during the second quarter, HoldingsChannel.com reports. The fund owned 13,489 shares of the company’s stock after acquiring an additional 480 shares during the period. Eli Lilly and Company makes up approximately 1.5% of Silicon Valley Capital Partners’ holdings, making the stock its 19th largest holding. Silicon Valley Capital Partners’ holdings in Eli Lilly and Company were worth $16,179,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $12,976,634,000. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company in the second quarter worth $13,522,666,000. Jupiter Topco LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter worth $4,667,180,000. Fifth Third Bancorp boosted its stake in Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after buying an additional 1,497,423 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in Eli Lilly and Company by 353.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock valued at $1,425,859,000 after buying an additional 1,208,510 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company Price Performance
NYSE LLY traded up $12.69 during trading hours on Monday, reaching $1,165.62. 2,232,094 shares of the stock traded hands, compared to its average volume of 3,023,233. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock has a 50 day simple moving average of $1,176.90 and a two-hundred day simple moving average of $1,077.21. Eli Lilly and Company has a 1 year low of $712.05 and a 1 year high of $1,292.65. The company has a market cap of $1.10 trillion, a price-to-earnings ratio of 39.11, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50.
Analysts Set New Price Targets
A number of equities analysts have weighed in on LLY shares. Guggenheim upped their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday. Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a research report on Tuesday, September 15th. Bank of America boosted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. HSBC upped their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,305.25.
View Our Latest Analysis on Eli Lilly and Company
Trending Headlines about Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Approximately 700,000 seniors have started GLP-1 treatments since new Medicare coverage began in July, and about 70% are using Eli Lilly medicines. The data suggests Medicare could materially expand the company’s addressable obesity-treatment market. Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage
- Positive Sentiment: CEO David Ricks said roughly one-third of newly prescribed GLP-1 pills are Lilly’s Foundayo, prompting the company to increase production. Strong early adoption supports the outlook for Lilly’s oral obesity-drug franchise. Lilly is ramping up future manufacturing for Foundayo obesity pill
- Positive Sentiment: Lilly is breaking ground on a planned $6.5 billion Houston manufacturing facility, reinforcing management’s confidence in long-term demand and expanding capacity for future medicines. Eli Lilly to host groundbreaking of $6.5 billion facility
- Neutral Sentiment: A completed early-stage study of LY3971297 moves Lilly’s cardio-metabolic pipeline toward the next development steps, but no efficacy or safety results were reported, limiting the immediate investment impact. Eli Lilly’s LY3971297 trial completion
- Neutral Sentiment: Commentary noted that Lilly’s revenue is growing rapidly while the stock has been comparatively weak this year, suggesting investors may be discounting valuation, competition, or the sustainability of GLP-1 growth.
- Negative Sentiment: Investor concerns about Novo Nordisk’s pipeline intensified after data indicated its CagriSema combination outperformed Lilly’s tirzepatide in a weight-loss trial. The development underscores increasing competitive risk in Lilly’s core obesity market. Novo Nordisk falls as competition concerns persist
Insider Buying and Selling
In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 in the last quarter. 0.14% of the stock is owned by insiders.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.
The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
